

# Ryan P Hickson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4046846/publications.pdf>

Version: 2024-02-01

16  
papers

300  
citations

1040056

9  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Online Medical Care: The Current State of “Visits” in Acute Primary Care Delivery. <i>Telemedicine Journal and E-Health</i> , 2015, 21, 90-96.	2.8	65
2	Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1543-1554.	2.8	65
3	Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	26
4	Clinical and economic impact of meropenem resistance in <i>Pseudomonas aeruginosa</i> infected patients. <i>American Journal of Infection Control</i> , 2016, 44, 1275-1279.	2.3	24
5	Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: An example using real-world statin adherence data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 357-362.	1.9	23
6	Development of a new diabetes medication self-efficacy scale and its association with both reported problems in using diabetes medications and self-reported adherence. <i>Patient Preference and Adherence</i> , 2016, 10, 1003.	1.8	22
7	It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality. <i>Journal of the American Heart Association</i> , 2019, 8, e011378.	3.7	19
8	Evaluation of a pharmaceutical assessment screening tool to measure patient acuity and prioritise pharmaceutical care in a UK hospital. <i>European Journal of Hospital Pharmacy</i> , 2017, 24, 74-79.	1.1	16
9	Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1087-1093.	2.1	9
10	Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 72-79.	0.9	9
11	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers after an Acute Myocardial Infarction. <i>Pharmacotherapy</i> , 2018, 38, 29-41.	2.6	8
12	Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States. <i>Cancer Epidemiology</i> , 2018, 55, 8-16.	1.9	5
13	Comparing Continuous and Binary Group-based Trajectory Modeling Using Statin Medication Adherence Data. <i>Medical Care</i> , 2021, 59, 997-1005.	2.4	5
14	The electronic medication complete communication (EMC2) study: Rationale and methods for a randomized controlled trial of a strategy to promote medication safety in ambulatory care. <i>Contemporary Clinical Trials</i> , 2016, 51, 72-77.	1.8	2
15	Disparities by sex in P2Y <sub>12</sub> inhibitor therapy duration, or differences in the balance of ischaemic-benefit and bleeding-risk clinical outcomes in older women versus comparable men following acute myocardial infarction? A P2Y <sub>12</sub> inhibitor new user retrospective cohort analysis of US Medicare claims data. <i>BMI Open</i> , 2021, 11, e050236.	1.9	1
16	Predictors of Î²-Blocker Initiation After Myocardial Infarction in Patients With Type 2 Diabetes. <i>Journal of Pharmacy Technology</i> , 2016, 32, 160-168.	1.0	0